Amneal Pharmaceuticals, Inc. (AMRX) stock soared 5.02% in Monday's intraday trading session. The surge came after several analysts maintained their bullish ratings on the pharmaceutical company's stock.
Truist Financial analyst Les Sulewski reiterated a "Buy" rating on Amneal, citing the company's strong fundamentals and growth prospects. Meanwhile, Barclays also kept an "Overweight" rating on the stock, indicating their confidence in the company's performance.
Positive analyst coverage and ratings typically boost investor sentiment, which could have contributed to the significant rise in Amneal's stock price on Monday. The company's shares closed the trading session higher, reflecting the market's optimism about its future outlook.